This $299,982 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) aims to evaluate the safety and efficacy of Unandup, LLC's novel adjunctive thrombolysis platform for treating acute ischemic stroke (AIS). The platform is designed to accelerate the delivery of the clot-dissolving drug alteplase to the obstructing blood clot, thereby improving outcomes for AIS patients. Specifically, the funding will support in vivo preclinical testing of the platform in a rat embolic middle cerebral arterial occlusion model to advance this technology toward potential future clinical studies and regulatory approval. The award period runs from March 2025 to February 2026.